Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS) — Stock Score Summary

Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS) has a MoatMap StockRank of 94/100 based on Quality (79/100), Value (63/100), and Momentum (41/100) factor scores. The current signal is STRONG BUY. Tibet Rhodiola Pharmaceutical is a Chinese pharmaceutical company. It faces severe domestic regulatory risks, including China's Volume-Based Procurement (VBP) policy, which structurally compresses drug pricing and margins.

Tibet Rhodiola Pharmaceutical Holding Co. develops, manufactures, and markets cardiovascular, biopharmaceutical, and traditional Tibetan medicines. Its competitive moat is anchored by proprietary products like XinHuo (recombinant human brain natriuretic peptide) and exclusive access to high-altitude herbal resources. The company operates as a highly profitable niche player in the specialty cardiovascular segment.

Key Financial Metrics

Price$5.24
Market Cap$1.8B
P/E (TTM)12.53
P/E (Forward)9.03
Price/Book3.07
Return on Equity22.2%
Return on Invested Capital22.8%
Debt/Equity25.10
Gross Margin93.8%
Operating Margin29.7%
Revenue Growth1.6%
Dividend Yield9.3%
Free Cash Flow$14M

Tibet Rhodiola Pharmaceutical Holding Co. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Tibet Rhodiola Pharmaceutical Holding Co.’s (600211.SS) StockRank?
MoatMap’s StockRank for Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS) is 94/100, with a Strong Buy signal. It is a composite of Quality (79), Value (63), and Momentum (41) factor ranks across MoatMap’s 19,000+ stock universe.
Does Tibet Rhodiola Pharmaceutical Holding Co. have an economic moat?
Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS) has a Quality factor score of 79/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Tibet Rhodiola Pharmaceutical Holding Co. a buy, hold, or sell?
MoatMap’s current signal for Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS) is Strong Buy, based on a StockRank of 94/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Tibet Rhodiola Pharmaceutical Holding Co. in?
Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).
Browse all ranked stocks600211.SS deep dive reportAI ChampionsHow we score stocksSense-check another stock